Immunogenicity and protective efficacy of rotavirus VP8* fused to cholera toxin B subunit in a mouse model

References

• Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque J, Parashar UD. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:136-41; PMID:22030330; http://dx.doi.org/10.1016/S1473-3099(11)70253-5
   PubMed Web of Science ®Google Scholar
• Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003; 9:565-72; PMID:12737740; http://dx.doi.org/10.3201/eid0905.020562
   PubMed Web of Science ®Google Scholar
• Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, Abate H, Breuer T, Clemens SAC, Cheuvart B, Espinoza F, Gillard P, Innis BL, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354:11-22; PMID:16394298; http://dx.doi.org/10.1056/NEJMoa052434
   PubMed Web of Science ®Google Scholar
• Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354:23-33; PMID:16394299; http://dx.doi.org/10.1056/NEJMoa052664
   PubMed Web of Science ®Google Scholar
• Bhandari N, Rongsen-Chandola T, Bavdekar A, John J, Antony K, Taneja S, Goyal N, Kawade A, Kang G, Rathore SS, et al. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial. Lancet 2014; 383:2136-43; PMID:24629994; http://dx.doi.org/10.1016/S0140-6736(13)62630-6
   PubMed Web of Science ®Google Scholar
• Tate JE, Arora R, Kang G, Parashar UD. Rotavirus vaccines at the threshold of implementation in India. Natl Med J India 2014; 27:245-8; PMID:26037421
   PubMed Web of Science ®Google Scholar
• Sow SO, Tapia M, Haidara FC, Ciarlet M, Diallo F, Kodio M, Doumbia M, Dembélé RD, Traoré O, Onwuchekwa UU, et al. Efficacy of the oral pentavalent rotavirus vaccine in Mali. Vaccine 2012; 30 Suppl 1:A71-8; PMID:22520140; http://dx.doi.org/10.1016/j.vaccine.2011.11.094
   PubMedGoogle Scholar
• Cunliffe NA, Witte D, Ngwira BM, Todd S, Bostock NJ, Turner AM, Chimpeni P, Victor JC, Steele AD, Bouckenooghe A, et al. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial. Vaccine 2012; 30 Suppl 1:A36-43; PMID:22520135; http://dx.doi.org/10.1016/j.vaccine.2011.09.120
   PubMed Web of Science ®Google Scholar
• Zaman K, Anh DD, Victor JC, Shin S, Yunus M, Dallas MJ, Podder G, Thiem VD, Mai LTP, Luby SP. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 376:568-70; http://dx.doi.org/10.1016/S0140-6736(10)60755-6
   PubMed Web of Science ®Google Scholar
• Armah GE, Sow SO, Breiman RF, Dallas MJ, Tapia MD, Feikin DR, Binka FN, Steele AD, Laserson KF, Ansah NA, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 376:606-14; PMID:20692030; http://dx.doi.org/10.1016/S0140-6736(10)60889-6
   PubMed Web of Science ®Google Scholar
• Greenberg HB. Rotavirus vaccination and intussusception–act two. N Engl J Med 2011; 364:2354-5; PMID:21675894; http://dx.doi.org/10.1056/NEJMe1105302
   PubMed Web of Science ®Google Scholar
• Weintraub ES, Baggs J, Duffy J, Vellozzi C, Belongia EA, Irving S, Klein NP, Glanz JM, Jacobsen SJ, Naleway A, et al. Risk of intussusception after monovalent rotavirus vaccination. N Engl J Med 2014; 370:513-9; PMID:24422678; http://dx.doi.org/10.1056/NEJMoa1311738
   PubMed Web of Science ®Google Scholar
• Rose TL, Marques da Silva MF, Gomez MM, Resque HR, Ichihara MY, Volotao Ede M, Leite JP. Evidence of vaccine-related reassortment of rotavirus, Brazil, 2008-2010. Emerg Infect Dis 2013; 19:1843-6; PMID:24188273; http://dx.doi.org/10.3201/eid1911.121407
   PubMed Web of Science ®Google Scholar
• Donato CM, Ch'ng LS, Boniface KF, Crawford NW, Buttery JP, Lyon M, Bishop RF, Kirkwood CD. Identification of strains of RotaTeq rotavirus vaccine in infants with gastroenteritis following routine vaccination. J Infect Dis 2012; 206:377-83; PMID:22615314; http://dx.doi.org/10.1093/infdis/jis361
   PubMed Web of Science ®Google Scholar
• Bucardo F, Rippinger CM, Svensson L, Patton JT. Vaccine-derived NSP2 segment in rotaviruses from vaccinated children with gastroenteritis in Nicaragua. Infect Genet Evol 2012; 12:1282-94; PMID:22487061; http://dx.doi.org/10.1016/j.meegid.2012.03.007
   PubMed Web of Science ®Google Scholar
• Boom JA, Sahni LC, Payne DC, Gautam R, Lyde F, Mijatovic-Rustempasic S, Bowen MD, Tate JE, Rench MA, Gentsch JR, et al. Symptomatic infection and detection of vaccine and vaccine-reassortant rotavirus strains in 5 children: a case series. J Infect Dis 2012; 206:1275-9; PMID:22872730; http://dx.doi.org/10.1093/infdis/jis490
   PubMed Web of Science ®Google Scholar
• Hemming M, Vesikari T. Detection of rotateq vaccine-derived, double-reassortant rotavirus in a 7-year-old child with acute gastroenteritis. Pediatr Infect Dis J 2014; 33:655-6; PMID:24326415; http://dx.doi.org/10.1097/INF.0000000000000221
   PubMed Web of Science ®Google Scholar
• Wen X, Cao D, Jones RW, Li J, Szu S, Hoshino Y. Construction and characterization of human rotavirus recombinant VP8* subunit parenteral vaccine candidates. Vaccine 2012; 30:6121-6; PMID:22885016; http://dx.doi.org/10.1016/j.vaccine.2012.07.078
   PubMed Web of Science ®Google Scholar
• Li T, Lin H, Zhang Y, Li M, Wang D, Che Y, Zhu Y, Li S, Zhang J, Ge S, et al. Improved characteristics and protective efficacy in an animal model of E. coli-derived recombinant double-layered rotavirus virus-like particles. Vaccine 2014; 32:1921-31; PMID:24530406; http://dx.doi.org/10.1016/j.vaccine.2014.01.093
   PubMed Web of Science ®Google Scholar
• Ward RL, McNeal MM. VP6: A candidate rotavirus vaccine. J Infect Dis 2010; 202 Suppl:S101-7; PMID:20684688; http://dx.doi.org/10.1086/653556
   PubMedGoogle Scholar
• Khodabandehloo M, Shahrabadi MS, Keyvani H, Bambai B, Sadigh Z. Recombinant outer capsid glycoprotein (VP7) of rotavirus expressed in insect cells induces neutralizing antibodies in rabbits. Iran J Public Health 2012; 41:73-84; PMID:23113180
   PubMed Web of Science ®Google Scholar
• Xie L, Yan M, Wang X, Ye J, Mi K, Yan S, Niu X, Li H, Sun M. Immunogenicity and efficacy in mice of an adenovirus-based bicistronic rotavirus vaccine expressing NSP4 and VP7. Virus Res 2015; 210:298-307; PMID:26368053; http://dx.doi.org/10.1016/j.virusres.2015.09.010
   PubMed Web of Science ®Google Scholar
• Mackow ER, Vo PT, Broome R, Bass D, Greenberg HB. Immunization with baculovirus-expressed VP4 protein passively protects against simian and murine rotavirus challenge. J Virol 1990; 64:1698-703; PMID:2157052
   PubMed Web of Science ®Google Scholar
• Offit PA. Rotaviruses: immunological determinants of protection against infection and disease. Adv Virus Res 1994; 44:161-202; PMID:7817873; http://dx.doi.org/10.1016/S0065-3527(08)60329-2
   PubMed Web of Science ®Google Scholar
• Settembre EC, Chen JZ, Dormitzer PR, Grigorieff N, Harrison SC. Atomic model of an infectious rotavirus particle. EMBO J 2011; 30:408-16; PMID:21157433; http://dx.doi.org/10.1038/emboj.2010.322
   PubMed Web of Science ®Google Scholar
• References S, Estes M, Graham D, Mason B. Proteolytic enhancement of rotavirus infectivity: molecular mechanisms. J Virol 1981; 39:879-88; PMID:6270356
   PubMed Web of Science ®Google Scholar
• Wen X, Wen K, Cao D, Li G, Jones RW, Li J, Szu S, Hoshino Y, Yuan L. Inclusion of a universal tetanus toxoid CD4 T cell epitope P2 significantly enhanced the immunogenicity of recombinant rotavirus DeltaVP8* subunit parenteral vaccines. Vaccine 2014; 32:4420-7; PMID:24962749; http://dx.doi.org/10.1016/j.vaccine.2014.06.060
   PubMed Web of Science ®Google Scholar
• Fix AD, Harro C, McNeal M, Dally L, Flores J, Robertson G, Boslego JW, Cryz S. Safety and immunogenicity of a parenterally administered rotavirus VP8 subunit vaccine in healthy adults. Vaccine 2015; 33:3766-72; PMID:26065919; http://dx.doi.org/10.1016/j.vaccine.2015.05.024
   PubMed Web of Science ®Google Scholar
• Xue M, Yu L, Che Y, Lin H, Zeng Y, Fang M, Li T, Ge S, Xia N. Characterization and protective efficacy in an animal model of a novel truncated rotavirus VP8 subunit parenteral vaccine candidate. Vaccine 2015; 33:2606-13; PMID:25882173; http://dx.doi.org/10.1016/j.vaccine.2015.03.068
   PubMed Web of Science ®Google Scholar
• Jackson LA, Gurtman A, van Cleeff M, Jansen KU, Jayawardene D, Devlin C, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 2013; 31:3577-84; PMID:23688526; http://dx.doi.org/10.1016/j.vaccine.2013.04.085
   PubMed Web of Science ®Google Scholar
• Lycke N, Holmgren J. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology 1986; 59:301-8; PMID:3021614
   PubMed Web of Science ®Google Scholar
• Stratmann T. Cholera toxin subunit B as adjuvant–an accelerator in protective immunity and a break in autoimmunity. Vaccines (Basel) 2015; 3:579-96; PMID:26350596; http://dx.doi.org/10.3390/vaccines3030579
   PubMed Web of Science ®Google Scholar
• Marchioro SB, Fisch A, Gomes CK, Jorge S, Galli V, Haesebrouck F, Maes D, Dellagostin O, Conceição FR. Local and systemic immune responses induced by a recombinant chimeric protein containing Mycoplasma hyopneumoniae antigens fused to the B subunit of Escherichia coli heat-labile enterotoxin LTB. Vet Microbiol 2014; 173:166-71; PMID:25091529; http://dx.doi.org/10.1016/j.vetmic.2014.07.009
   PubMed Web of Science ®Google Scholar
• Bharati K, Ganguly NK. Cholera toxin: a paradigm of a multifunctional protein. Indian J Med Res 2011; 133:179-87; PMID:21415492
   PubMed Web of Science ®Google Scholar
• Ciarlet M, Crawford SE, Barone C, Bertolotti-Ciarlet A, Ramig RF, Estes MK, Conner ME. Subunit rotavirus vaccine administered parenterally to rabbits induces active protective immunity. J Virol 1998; 72:9233-46; PMID:9765471
   PubMed Web of Science ®Google Scholar
• Pan M, Jiang H Q, Zhou Y, Zheng J. Comparison of the role of Freund's adjuvant and aluminum hydroxide hydrate in inducing mouse adaptive immune response. Current Immunology 2006; 18:2082-93.
   Google Scholar
• Pizza M, Giuliani MM, Fontana MR, Monaci E, Douce G, Dougan G, Mills KH, Rappuoli R, Del Giudice G. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 2001; 19:2534-41; PMID:11257389; http://dx.doi.org/10.1016/S0264-410X(00)00553-3
   PubMed Web of Science ®Google Scholar
• Gruber WC, Scott DA, Emini EA. Development and clinical evaluation of Prevnar 13, a 13-valent pneumocococcal CRM197 conjugate vaccine. Ann N Y Acad Sci 2012; 1263:15-26; PMID:22830997; http://dx.doi.org/10.1111/j.1749-6632.2012.06673.x
   PubMed Web of Science ®Google Scholar
• Holmgren J, Adamsson J, Anjuere F, Clemens J, Czerkinsky C, Eriksson K, Flach CF, George-Chandy A, Harandi AM, Lebens M, et al. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol Lett 2005; 97:181-8; PMID:15752556; http://dx.doi.org/10.1016/j.imlet.2004.11.009
   PubMed Web of Science ®Google Scholar
• Harakuni T, Sugawa H, Komesu A, Tadano M, Arakawa T. Heteropentameric cholera toxin B subunit chimeric molecules genetically fused to a vaccine antigen induce systemic and mucosal immune responses: a potential new strategy to target recombinant vaccine antigens to mucosal immune systems. Infect Immun 2005; 73:5654-65; PMID:16113283; http://dx.doi.org/10.1128/IAI.73.9.5654-5665.2005
   PubMed Web of Science ®Google Scholar
• Pecetta S, Lo Surdo P, Toritini M, Proietti D, Zambonelli C, Bottomley MJ, Biagini M, Berti F, Costantino P, Romano MR, et al. Carrier priming with CRM197 or diphtheria toxoid has a different impact on the immunogenicity of the respective glycoconjugates: Biophysical and immunochemical interpretation. Vaccine 2015; 33:314-20; PMID:25448110; http://dx.doi.org/10.1016/j.vaccine.2014.11.026
   PubMed Web of Science ®Google Scholar
• Baldauf KJ, Royal JM, Hamorsky KT, Matoba N. Cholera toxin B: one subunit with many pharmaceutical applications. Toxins (Basel) 2015; 7:974-96; PMID:25802972; http://dx.doi.org/10.3390/toxins7030974
   PubMed Web of Science ®Google Scholar
• Santos N, Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol 2005; 15:29-56; PMID:15484186; http://dx.doi.org/10.1002/rmv.448
   PubMed Web of Science ®Google Scholar
• Istrate C, Hinkula J, Charpilienne A, Poncet D, Cohen J, Svensson L, Johansen K. Parenteral administration of RF 8-2/6/7 rotavirus-like particles in a one-dose regimen induce protective immunity in mice. Vaccine 2008; 26:4594-601; PMID:18588935; http://dx.doi.org/10.1016/j.vaccine.2008.05.089
   PubMed Web of Science ®Google Scholar
• El-Attar L, Oliver SL, Mackie A, Charpilienne A, Poncet D, Cohen J, Bridger JC. Comparison of the efficacy of rotavirus VLP vaccines to a live homologous rotavirus vaccine in a pig model of rotavirus disease. Vaccine 2009; 27:3201-8; PMID:19446192; http://dx.doi.org/10.1016/j.vaccine.2009.03.043
   PubMed Web of Science ®Google Scholar
• Arnold M, Patton JT, McDonald SM. Culturing, storage, and quantification of rotaviruses. Curr Protoc Microbiol 2009; 15:C.3.1-C.3.24.
   Google Scholar
• Li T, Lin H, Yu L, Xue M, Ge S, Zhao Q, Zhang J, Xia N. Development of an enzyme-linked immunospot assay for determination of rotavirus infectivity. J Virol Methods 2014; 209:7-14; PMID:25172048; http://dx.doi.org/10.1016/j.jviromet.2014.08.012
   PubMed Web of Science ®Google Scholar
• Zhang C. Hybridoma technology for the generation of monoclonal antibodies. In: Proetzel G, Ebersbach H, eds. Antibody Methods and Protocols. Berlin: Springer, 2012; 117-35.
   Google Scholar
• Luo WX, Zhang J, Yang HJ, Li SW, Xie XY, Pang SQ, Li SJ, Xia NS. Construction and application of an Escherichia coli high effective expression vector with an enhancer. Sheng Wu Gong Cheng Xue Bao 2000; 16:578-81; PMID:11191761
   PubMedGoogle Scholar
• Buragohain M, Dhale GS, Raut CG, Kang G, Chitambar SD. Analyses of clinical, pathological and virological features of human rotavirus strain, YO induced gastroenteritis in infant BALB/c mice. Microbes and Infection 2011; 13:331-8; PMID:21163362; http://dx.doi.org/10.1016/j.micinf.2010.12.001
   PubMed Web of Science ®Google Scholar
• Lee GL. Munual of histological staining methods of the Armed Forces Institute of Pathology. New York: Blakiston Divison,McGraw-Hill; 1968; 258 p.
   Google Scholar